Vitamin D3 Supplementation for AlloHSCT-RCT
Launched by UNIVERSITY OF BRITISH COLUMBIA · May 11, 2018
Trial Information
Current as of May 16, 2025
Unknown status
Keywords
ClinConnect Summary
This is a randomized non-blinded single centre prospective clinical trial designed to validate whether a single oral loading dose of 100,000 IU vitamin D3 prior to allogeneic hematopoietic stem cell transplant (aHSCT) can achieve optimal 25 hydroxy-vitamin D3(25-OH-D3) levels (\>75nmol/L) at one month post aHSCT, and maintain adequate levels for at least three months, compared to our standard practice of 2000 IU vitamin D3 daily.
84 patients will be enrolled. Following completion of all baseline data collection, participants will be randomized 1:1 to the intervention group or the control g...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients undergoing allogeneic stem cell transplantation at the Leukemia/BMT Program of British Columbia.
- • 2. Age greater than or equal to 18 years.
- • 3. Able to provide written informed consent.
- Exclusion Criteria:
- • 1. Hypercalcemia, hypervitaminosis D, or allergic/ sensitive to vitamin D.
- • 2. Not meeting eligibility criteria to proceed with allogeneic stem cell transplantation as per the Leukemia/BMT Program of BC.
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Raewyn Broady, MBChB
Principal Investigator
British Columbia Cancer Agency
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials